TELA - NASDAQ
TELA Bio, Inc.
$1.14
+0.44%TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
At a Glance
Live SnapshotTELA Bio, Inc. Management Team
Mr. Gregory A. Firestone
Chief Commercial Officer
Mr. Peter C. Murphy
Chief Commercial Officer
Compensation
$542,339
Mr. Roberto E. Cuca J.D.
Chief Financial Officer & Chief Operating Officer
Compensation
$668,379
Mr. Paul Talmo
Chief Technology Officer
Compensation
$580,554
Mr. Antony Koblish
Co-founder, President, Chief Executive Officer & Director
Compensation
$1,010,015
Mr. D. Taylor Ocasio
General Counsel & Corporate Secretary
Louisa Smith
Investor Relations Contact Officer
Ms. Jennifer Lou Armstrong
Senior Vice President of Human Resources
Mr. Michael Leonard
Senior Vice President of Technical Operations
Ms. Megan Smeykal
Vice President, Corporate Controller, Chief Accounting Officer & Principal Accounting Officer
TELA Bio, Inc. Insider Positioning
During the last 12 months, insiders have purchased $4.00M and sold $2K worth of TELA shares, resulting in $4.00M of net buying activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
3.6M
4.00M
0
0.00
+4.0M
+$4.00M
9-12 Months
0
0.00
1.1K
2.03K
-2K
-$2K
Top Buyers
Ew Healthcare Partners Fund 2, L.P.
10 Percent Owner, Other: See Remarks
$4.00M
Top Sellers
Firestone Gregory A.
Officer: Chief Commercial Officer
$2K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $4.00M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Insider Participation
1 insider buyers and 1 sellers. Equal participation suggests mixed or neutral insider views.
SEC Filings
TELA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 30, 2026 | June 09, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 17, 2025 | May 28, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 18, 2024 | June 04, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 17, 2023 | June 01, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 21, 2022 | June 01, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 22, 2021 | June 02, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 23, 2020 | June 04, 2020 | 2020 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.